New drug combo for rare blood disease under safety review
NCT ID NCT07413679
First seen Feb 22, 2026 · Last updated May 09, 2026 · Updated 15 times
Summary
This study looks at the long-term safety of danicopan when added to standard treatments for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will analyze data from 50 adults already taking danicopan alongside eculizumab or ravulizumab. The goal is to track serious side effects and understand why some people stop the medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alexion Pharmaceuticals, Inc. (Sponsor)
Boston, Massachusetts, 02210, United States
Conditions
Explore the condition pages connected to this study.